A Single Dose Could Reshape Immunity Against the Deadliest Viruses

A team of researchers from the Massachusetts Institute of Technology (MIT) and the Scripps Research Institute has developed a groundbreaking method to enhance the immune response against HIV using just a single vaccine dose, by combining two powerful immune-boosting agents.

In experiments conducted on mice, results showed that the combination of traditional “alum” and a new immune adjuvant called SMNP led to the production of more diverse and larger quantities of antibodies, compared to using the vaccine alone or with just one adjuvant. This development not only opens promising avenues for HIV prevention, but could also accelerate the creation of effective single-dose vaccines for other infectious diseases such as COVID-19 and influenza.

The researchers based their study on a modified HIV protein known as MD39, used as an antigen attached to alum particles with the addition of SMNP. Following vaccination, the team observed that this combination remained stable in lymph nodes for up to a month, giving the immune system more time to build a strong and targeted response.

Professor J. Christopher Love, one of the lead researchers, explained:
“This method mimics what happens during natural infection, where the antigen remains in the body for a long time, giving immune cells the opportunity to strengthen their defenses.”

By analyzing B cells in the mice, researchers found that the enhanced vaccine produced a broader and greater quantity of antibodies, increasing the likelihood of generating “broadly neutralizing” antibodies capable of targeting multiple strains of HIV.

Love added:
“The more opportunities we give the immune system to explore different options, the higher the chances of producing effective antibodies against a wider range of viruses.”

The study, published in Science Translational Medicine, suggests that the approach can be applied to protein-based vaccines for various diseases. Additionally, the components used are already familiar to health authorities, which could speed up regulatory approval.

Love concluded:
“The true strength of this approach lies in its simplicity and effectiveness. It doesn’t require new technologies, just a smarter use of existing tools to develop stronger, faster vaccines.”

The research was supported by the U.S. National Institutes of Health (NIH), the Koch Institute, the Ragon Institute, and the Howard Hughes Medical Institute.